FIGURE 7.

Binding of rCvGal1 to whole hemocytes. A, binding of rCvGal1 (100 μg/ml) to hemocytes in the presence of PSM (300 μg/ml), ASF (1 mg/ml), or BSA (1 mg/ml). * indicates significant different (p < 0.05) from sample without inhibitor (−). B, binding of rCvGal1 (100 μg/ml) to hemocytes in the presence of PSM (0–300 μg/ml). Sample without exogenous rCvGal1 and inhibitor was shown (Ctrl). * indicates significant difference (p < 0.05) from sample without inhibitor (0). C, fixed hemocytes were stained with dilutions of anti-blood group A antibody (red, 1:2000; blue, 1:500; yellow, 1:100) or buffer only (black) in flow cytometry analysis. Data show histogram of each sample. D, fixed cells were preincubated with CvGal1 (100 μg/ml) and stained with anti-blood group A antibody. Data show mean fluorescence intensity (MFI) ± S.E. (left panel) of each sample. * indicates significant difference (p < 0.05) from sample without CvGal1 preincubation (0). Sample without antibody staining was shown (Ctrl). E, fixed cells were preincubated with anti-blood group A antibody (1:100), and the binding of rCvGal1 (100 μg/ml) was measured. * indicates significant difference (p < 0.05) from sample without antibody preincubation (0). Sample without rCvGal1 was shown (Ctrl).